Compare NVRI & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVRI | CERS |
|---|---|---|
| Founded | 1853 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | EDP Services |
| Sector | Miscellaneous | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 582.1M | 534.0M |
| IPO Year | 2026 | 1996 |
| Metric | NVRI | CERS |
|---|---|---|
| Price | $19.90 | $2.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $28.67 | $5.13 |
| AVG Volume (30 Days) | 244.7K | ★ 1.8M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 77.20% | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $51,326,000.00 |
| Revenue This Year | N/A | $20.82 |
| Revenue Next Year | N/A | $9.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $11.15 | $1.38 |
| 52 Week High | $24.20 | $3.47 |
| Indicator | NVRI | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 47.33 | 35.77 |
| Support Level | $18.65 | $2.20 |
| Resistance Level | $20.65 | $3.12 |
| Average True Range (ATR) | 0.68 | 0.08 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 59.09 | 26.67 |
Enviri Corp provides environmental and operational solutions to the metal and rail industries. It is based in Philadelphia, Pennsylvania, and operates in more than 30 countries. The company leverages industrial expertise to help customers improve operational performance, recover value from byproducts, enhance sustainability, and maintain critical infrastructure. Its divisions are Harsco Environmental and Harsco Rail, which combine deep operational capabilities with technologies and world-wide scale to deliver long-term value for customers, communities, and shareholders.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.